MedTAS partners with leading global manufacturers to bring high-quality, affordable generic medicines to patients â navigating every step from patent strategy to PBS listing.
In just five years, MedTAS has grown from a bold idea into one of Australia's most dynamic generic pharmaceutical companies â driven by deep expertise, strategic partnerships, and an unwavering focus on patient access.
MedTAS was born from a bold conviction: that no patient in Australia should ever go without essential medicine because of cost. We're not just another pharmaceutical distributor â we're a purpose-driven team of regulatory strategists, commercial specialists, and supply chain experts who wake up every day determined to break down the barriers between world-class generics and the patients who need them.
From our Sydney headquarters, we partner with the best GMP-certified manufacturers on the planet, navigate the most complex regulatory pathways in the region, and deliver medicines that meet the highest standards of quality at prices that put patients first. This is more than business. This is what we were built to do.
Every Australian deserves affordable, quality medicines without exception
Complete transparency in every regulatory, commercial, and supply chain decision
Pharmaceutical compliance demands accuracy â we never cut corners on quality or regulation
Invested in your product's entire lifecycle â we succeed only when our partners succeed
From molecule identification to patient delivery, we manage every critical step in the lifecycle of a generic medicine in Australia.
We continuously scan the global pipeline and patent landscape to identify high-value generic opportunities aligned with Australian market demand.
Our regulatory team manages TGA dossier submissions from CTD compilation through to ARTG listing and post-approval variations.
We conduct thorough freedom-to-operate analyses and develop launch strategies that balance speed to market with robust IP protection.
We prepare PBAC submissions, negotiate pricing under the National Health Act, and manage ongoing PBS listing obligations.
From GMP-certified manufacturers globally to temperature-controlled logistics across Australia, we manage the entire supply chain.
Our PV team maintains robust post-market safety monitoring systems ensuring ongoing TGA compliance.
Our proven end-to-end model takes a generic medicine from identification through to the pharmacy shelf â efficiently, compliantly, and at the right price.
Scan patent landscapes and market data for the highest-value generic opportunities in the Australian market.
Partner with GMP manufacturers to develop formulations and conduct bioequivalence studies to international standards.
Compile CTD dossiers and manage TGA evaluation from submission through to ARTG listing approval.
Prepare PBAC submissions and negotiate PBS pricing so patients can access medicines at subsidised rates.
Manage supply chain logistics, distribution, pharmacovigilance, and ongoing compliance post-launch.
Our robust pipeline and expanding portfolio reflect our commitment to addressing unmet demand for affordable generics across key therapeutic categories.
Our existing ARTG-registered portfolio spans critical therapeutic areas with a strong focus on chronic disease management:
Our development pipeline targets high-demand molecules approaching patent expiry with a focus on:
We strategically focus on therapeutic areas where affordable generic alternatives have the greatest impact on patient outcomes and healthcare sustainability.
Antihypertensives, statins, anticoagulants, ACE inhibitors, ARBs, beta-blockers, and heart failure therapies for Australia's leading cause of death.
SSRIs, SNRIs, anxiolytics, anticonvulsants, and neuropathic pain agents â addressing mental health at scale across Australia.
Bronchodilators, inhaled corticosteroids, LABA/ICS combinations, and leukotriene modifiers for asthma and COPD management.
Penicillins, cephalosporins, macrolides, fluoroquinolones, antifungals, and antiviral agents for community and hospital settings.
Metformin, sulfonylureas, DPP-4 inhibitors, thyroxine, and hormonal therapies for diabetes and metabolic disorders.
NSAIDs, DMARDs, bisphosphonates, and muscle relaxants for arthritis, osteoporosis, and chronic pain management.
Antiemetics (5-HT3 antagonists), corticosteroids, analgesics, and supportive care medicines used alongside chemotherapy.
Proton pump inhibitors, H2 blockers, antispasmodics, aminosalicylates, and IBD therapies for digestive health conditions.
In a competitive generics landscape, our combination of regulatory depth, commercial agility, and global networks delivers results that larger organisations often can't match.
Our lean, experienced team moves faster than traditional pharma. We've taken products from dossier submission to PBS listing in under 18 months â well ahead of industry averages. Our pre-submission strategy means fewer TGA queries and faster evaluations.
Our regulatory affairs specialists have collectively managed 200+ TGA submissions. We understand the nuances of the ARTG registration process, PBAC submission cycles, and the regulatory quirks that can delay or derail a generic launch.
We translate between international manufacturers and Australian market realities. Our partners get a single point of contact who understands both global GMP standards and local TGA expectations â eliminating friction and miscommunication.
We don't hand off. From patent analysis through to pharmacovigilance, we own the product lifecycle end-to-end. One team accountable for quality, compliance, supply continuity, and commercial performance â no gaps, no finger-pointing.
Our size is our advantage. We evaluate new opportunities, make go/no-go decisions, and mobilise within weeks â not quarters. For manufacturers seeking a nimble Australian partner with real decision-making authority, MedTAS is the right fit.
Every pricing decision is anchored to a simple question: does this improve patient access? We work to secure the most competitive PBS pricing possible while maintaining commercially sustainable margins for our manufacturing partners.
You've invested years developing your product. You need an Australian partner who brings the same level of care, rigour, and urgency to getting it registered, reimbursed, and into patients' hands. That's exactly what MedTAS does.
Stop coordinating between regulatory consultants, IP lawyers, pricing advisors, and distributors. MedTAS handles the entire journey â from TGA dossier to pharmacy shelf â under one roof, with one accountable team.
In generics, the difference between first-to-market and fifth-to-market is the difference between success and irrelevance. Our lean team makes decisions in days, not months. No committees, no bureaucracy â just experienced people who know the Australian market inside out.
We believe great partnerships are built on trust, not fine print. You'll always know where your product stands â from regulatory milestones to commercial performance. We share data, flag risks early, and treat your business as if it were ours.
We structure partnerships that work commercially for both sides while keeping patient access at the centre. Our PBS pricing expertise ensures your product reaches the widest possible patient population at sustainable margins.
"We don't just distribute your product â we champion it. From the first regulatory strategy meeting to the day it reaches a patient, your molecule gets our full attention, expertise, and commitment."
â MedTAS Leadership TeamOur leadership team brings together decades of combined experience across pharmaceutical development, TGA regulatory affairs, PBS reimbursement, patent law, and Australian market access.
Mohit founded MedTAS with a clear mission: to make quality generic medicines affordable and accessible for every Australian. With a career spanning pharmaceutical commercialisation, regulatory strategy, and business development, he leads company vision, global partnerships, and market expansion. His entrepreneurial drive and deep understanding of the Australian generics landscape have been the driving force behind MedTAS's rapid growth from startup to a 100+ registration portfolio in just five years.
Alastair is a senior executive with over two decades of leadership experience across the pharmaceutical, healthcare, and FMCG sectors. Previously Finance Director and CFO at Amgen Australia, he has held senior roles at Vertex Pharmaceuticals, Alexion, and Alphapharm. A Harvard-trained executive leader, Chartered Accountant (Australia & UK), and AICD graduate, Alastair brings exceptional strategic, financial, and operational capability to MedTAS's growth trajectory.
Vikas leads MedTAS's regulatory strategy and TGA submission pipeline. With deep expertise in CTD dossier compilation, bioequivalence study oversight, and ARTG registration management, he has been instrumental in building MedTAS's 100+ approval portfolio. His experience spans global regulatory frameworks across Australia, Europe, and Asia, enabling seamless coordination between international manufacturing partners and Australian regulatory requirements.
Whether you're a global manufacturer seeking Australian market entry, a biotech exploring generic licensing, or a healthcare stakeholder looking for cost-effective alternatives â MedTAS is your strategic partner from dossier to dispensary.
Whether you have a partnership enquiry, a product question, or want to explore how MedTAS can support your market entry â reach out and we'll get back to you within 24 hours.
If you have experienced an unexpected reaction, side effect, or quality issue with a MedTAS product, please contact our Pharmacovigilance team immediately. Reporting adverse events is critical to patient safety and helps us work with the TGA to protect the Australian community. Healthcare professionals and consumers can report directly.
Important: Patients should always consult their doctor for medical advice about adverse events. MedTAS takes the protection of personal data seriously and may contact you for follow-up information. Reports are forwarded to the TGA as required under the Therapeutic Goods Act 1989.
Medtas Pty Ltd
Level 11, 347 Kent Street
Sydney CBD, NSW 2000, Australia
Phone: 1300 414 543
Email: info@medtas.com.au
ABN: 726 44270860
Website: www.medtas.com.au
Fill in the form below and our team will respond within one business day.